175 related articles for article (PubMed ID: 30306263)
1. Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-Kras
Vilimas T; Wang AQ; Patnaik S; Hughes EA; Singleton MD; Knotts Z; Li D; Frankowski K; Schlomer JJ; Guerin TM; Springer S; Drennan C; Dextras C; Wang C; Gilbert D; Southall N; Ferrer M; Huang S; Kozlov S; Marugan J; Xu X; Rudloff U
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1067-1080. PubMed ID: 30306263
[TBL] [Abstract][Full Text] [Related]
2. Safety assessment of metarrestin in dogs: A clinical candidate targeting a subnuclear structure unique to metastatic cancer cells.
Bourdi M; Rudloff U; Patnaik S; Marugan J; Terse PS
Regul Toxicol Pharmacol; 2020 Oct; 116():104716. PubMed ID: 32619635
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
[TBL] [Abstract][Full Text] [Related]
4. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
5. Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis.
Frankowski KJ; Wang C; Patnaik S; Schoenen FJ; Southall N; Li D; Teper Y; Sun W; Kandela I; Hu D; Dextras C; Knotts Z; Bian Y; Norton J; Titus S; Lewandowska MA; Wen Y; Farley KI; Griner LM; Sultan J; Meng Z; Zhou M; Vilimas T; Powers AS; Kozlov S; Nagashima K; Quadri HS; Fang M; Long C; Khanolkar O; Chen W; Kang J; Huang H; Chow E; Goldberg E; Feldman C; Xi R; Kim HR; Sahagian G; Baserga SJ; Mazar A; Ferrer M; Zheng W; Shilatifard A; Aubé J; Rudloff U; Marugan JJ; Huang S
Sci Transl Med; 2018 May; 10(441):. PubMed ID: 29769289
[TBL] [Abstract][Full Text] [Related]
6. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
7. Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice.
Moo KS; Radhakrishnan S; Teoh M; Narayanan P; Bukhari NI; Segarra I
Yao Xue Xue Bao; 2010 Jul; 45(7):901-8. PubMed ID: 20931790
[TBL] [Abstract][Full Text] [Related]
8. Determination of metarrestin (ML-246) in human plasma for a first-in-human clinical pharmacokinetic application by a simple and efficient uHPLC-MS/MS assay.
Richardson WJ; Zimmerman SM; Reno A; Corvalan Cabanas N; Arisa O; Rudloff U; Figg WD; Peer CJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 May; 1224():123738. PubMed ID: 37196527
[TBL] [Abstract][Full Text] [Related]
9. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
11. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive dynamic monitoring initiation and growth of pancreatic tumor in the LSL-Kras
Hu S; Pan L; Shangguan J; Figini M; Eresen A; Sun C; Wang B; Ma Q; Hu C; Yaghmai V; Velichko Y; Yang J; Zhang Z
J Immunol Methods; 2019 Feb; 465():1-6. PubMed ID: 30468734
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
[TBL] [Abstract][Full Text] [Related]
14. Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.
Krishnaswami S; Wang T; Yuan Y; Alvey CW; Checchio T; Peterson M; Shi H; Riese R
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):395-9. PubMed ID: 27137149
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Krishnaswami S; Boy M; Chow V; Chan G
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
17. Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer.
Pasquale V; Dugnani E; Liberati D; Marra P; Citro A; Canu T; Policardi M; Valla L; Esposito A; Piemonti L
Acta Diabetol; 2019 Sep; 56(9):1013-1022. PubMed ID: 30989379
[TBL] [Abstract][Full Text] [Related]
18. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan.
Rodriguez Lanzi C; Wei R; Luo D; Mackenzie GG
Neoplasia; 2022 Feb; 24(2):133-144. PubMed ID: 34968866
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer.
Goetze RG; Buchholz SM; Ou N; Zhang Q; Patil S; Schirmer M; Singh SK; Ellenrieder V; Hessmann E; Lu QB; Neesse A
Cells; 2019 Jun; 8(6):. PubMed ID: 31181844
[No Abstract] [Full Text] [Related]
20. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
Fendrich V; Sparn M; Lauth M; Knoop R; Plassmeier L; Bartsch DK; Waldmann J
Pancreatology; 2013; 13(5):502-7. PubMed ID: 24075515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
